A Multi-Centre Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Concizumab (Primary) ; Turoctocog alfa
- Indications Haemophilia A
- Focus Therapeutic Use
- Acronyms Explorer 5
- Sponsors Novo Nordisk
- 25 Aug 2017 Planned End Date changed from 8 Aug 2019 to 9 Aug 2019.
- 17 Aug 2017 Status changed from not yet recruiting to recruiting.
- 02 Jun 2017 New trial record